Steven M. Finkbeiner

Modeling human neurodegeneration with iPSCs: opportunities, limitations, and the challenge of aging

Most neurodegenerative diseases reflect patient-specific combinations of polygenic risk variants interacting with aging and environmental factors, rather than a single causative mutation. Phase III clinical trial failure rates for neurodegenerative indications exceed 95%, reflect...